



June 21, 2017

Attention: Application Examiner

RE: Request for Confidentiality
Applicant: Branchpoint Technologies, Inc.
FCC ID: 2AJW6-BTAIS-01

To Whom It May Concern:

Long-term Confidentiality

Request is hereby submitted by Branchpoint Technologies, Inc. to withhold permanently from public review certain portions of the application for equipment certification for the referenced FCC identifiers. This request for confidentiality is made pursuant to 47 CFR 0.457(d) and 0.459 of the FCC Rules. In particular, the following sections of the application are to be kept permanently confidential:

- Schematics
- Detailed Block Diagrams
- Detailed Operational/Functional Description
- Internal photos

The request to withhold and keep confidential the Internal Photos of the device is justified by the fact that the AURA™ Sensor circuit board is permanently welded into a metal can, which cannot be opened by the end user, and the AURA™ Antenna circuit board is permanently bonded into a plastic enclosure, which cannot be opened by the end user. Photos of the circuit boards with and without these enclosures have been submitted.

Short-term Confidentiality

Request is hereby submitted by Branchpoint Technologies to withhold from public review for a period of six (6) months from the date of the Grant of Equipment Authorization and prior to marketing, certain portions of the application for equipment certification for the referenced FCC identifiers. This request for confidentiality is made pursuant to 47 CFR 0.457(d) and 0.459 of the FCC Rules. In particular, the following sections of the application are to be kept confidential for a period of six (6) months from the date of Authorization:

- Test setup photos
- External photos
- User manual

Rationale for request for confidentiality:

Branchpoint Technologies, Inc. has invested considerable time and materials in research and development to produce the referenced product. Disclosure of the permanently confidential portions of this application to competitors would not only give them significant competitive advantages in developing similar products, but would also disclose successful implementation of unpublished, leading edge technology developed by us. Disclosure of the short-term confidential portions of this application during the period of review by the Food and Drug Administration and distribution would reveal key aspects of proprietary technology to competitors and diminish the value of our investment in research and development.

If you have questions or need further information, please contact the undersigned.

Sincerely,

A handwritten signature in black ink, appearing to read "Kevin Hughes".

Kevin Hughes
Chief Technology Officer
Branchpoint Technologies, Inc.